NasdaqCM - Delayed Quote USD

Outlook Therapeutics, Inc. (OTLK)

1.7500
+0.0750
+(4.48%)
At close: May 16 at 4:00:01 PM EDT
1.6925
-0.06
(-3.29%)
After hours: May 16 at 7:58:46 PM EDT
Advanced Chart
Loading Chart for OTLK
  • Previous Close 1.6750
  • Open 1.7000
  • Bid 1.7200 x 100
  • Ask 1.7800 x 100
  • Day's Range 1.6500 - 1.8000
  • 52 Week Range 0.8700 - 9.2500
  • Volume 320,795
  • Avg. Volume 421,414
  • Market Cap (intraday) 57.085M
  • Beta (5Y Monthly) 0.39
  • PE Ratio (TTM) 0.43
  • EPS (TTM) 4.0900
  • Earnings Date Aug 12, 2025 - Aug 18, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 11.20

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is headquartered in Iselin, New Jersey.

www.outlooktherapeutics.com

23

Full Time Employees

September 30

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

More about Outlook Therapeutics, Inc.

Recent News: OTLK

View More
View More

Performance Overview: OTLK

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

OTLK
7.41%
S&P 500 (^GSPC)
1.30%

1-Year Return

OTLK
76.13%
S&P 500 (^GSPC)
12.48%

3-Year Return

OTLK
94.53%
S&P 500 (^GSPC)
48.66%

5-Year Return

OTLK
87.81%
S&P 500 (^GSPC)
108.07%

Compare To: OTLK

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

OTLK
Outlook Therapeutics, Inc.
1.7500
+4.48%
Mkt Cap 57.085M
Industry Biotechnology
HEPA
Hepion Pharmaceuticals, Inc.
0.3180
0.00%
Mkt Cap 3.475M
Industry Biotechnology
CABA
Cabaletta Bio, Inc.
2.0300
+12.15%
Mkt Cap 103.008M
Industry Biotechnology
APLT
Applied Therapeutics, Inc.
0.6029
+22.82%
Mkt Cap 85.356M
Industry Biotechnology
XLO
Xilio Therapeutics, Inc.
0.8594
+7.42%
Mkt Cap 44.502M
Industry Biotechnology
RANI
Rani Therapeutics Holdings, Inc.
0.6406
+12.23%
Mkt Cap 37.67M
Industry Biotechnology
CTMX
CytomX Therapeutics, Inc.
2.0300
+1.50%
Mkt Cap 319.814M
Industry Biotechnology
INZY
Inozyme Pharma, Inc.
3.9500
+178.17%
Mkt Cap 255.019M
Industry Biotechnology
KTTA
Pasithea Therapeutics Corp.
0.9560
+11.09%
Mkt Cap 2.828M
Industry Biotechnology
PHAT
Phathom Pharmaceuticals, Inc.
4.0850
+17.39%
Mkt Cap 285.191M
Industry Biotechnology
NCNA
NuCana plc
0.0438
-17.98%
Mkt Cap 265,294
Industry Biotechnology

Statistics: OTLK

View More

Valuation Measures

Annual
As of 5/16/2025

  • Market Cap

    57.09M

  • Enterprise Value

    82.85M

  • Trailing P/E

    0.43

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -122.34%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    21.12M

  • Diluted EPS (ttm)

    4.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.56M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -35.91M

View More

Research Analysis: OTLK

View More
View More

Company Insights: OTLK

Research Reports: OTLK

View More
View More

People Also Watch

VTGN Vistagen Therapeutics, Inc.
2.4600
+6.96%
 
VTVT vTv Therapeutics Inc.
21.03
-6.12%
 
GHSI Guardion Health Sciences, Inc.
3.2200
0.00%
 
ITRM Iterum Therapeutics plc
0.9860
+6.20%
 
LPTX Leap Therapeutics, Inc.
0.4010
-2.67%
 
DARE Daré Bioscience, Inc.
2.8900
+0.35%
 
LPCN Lipocine Inc.
3.9900
+6.97%
 
OPGN OpGen, Inc.
4.9000
+4.26%
 
ADIL Adial Pharmaceuticals, Inc.
0.6578
-0.33%
 
XBIO Xenetic Biosciences, Inc.
2.9100
-3.32%
 
PRPO Precipio, Inc.
7.88
+10.21%
 
TENX Tenax Therapeutics, Inc.
5.89
+3.33%
 
PHIO Phio Pharmaceuticals Corp.
1.8400
+3.37%
 
BPTH Bio-Path Holdings, Inc.
0.1850
+2.78%
 
ASRT Assertio Holdings, Inc.
0.6658
+4.11%
 
FBIO Fortress Biotech, Inc.
1.8100
+1.69%